OptimizeRx Corporation — Q2 2021 Form 10-Q
Reporting period: Three and six months ended June 30, 2021; filed August 4, 2021. OptimizeRx provides digital health communications solutions connecting life sciences companies, healthcare providers, and patients.
Financial performance
| Metric | Q2 2021 | Q2 2020 | Six months 2021 | Six months 2020 |
|---|---|---|---|---|
| Revenue | $13.63 million | $8.78 million | $24.85 million | $16.37 million |
| Gross profit | $8.04 million | $5.14 million | $14.17 million | $9.49 million |
| Gross margin | 59.0% | 58.6% | 57.0% | 58.0% |
| Operating expenses | $7.70 million | $6.20 million | $14.47 million | $12.80 million |
| Operating income (loss) | $340,139 | ($1.06 million) | ($298,169) | ($3.32 million) |
| Net income (loss) | $352,100 | ($1.08 million) | ($285,277) | ($3.28 million) |
| EPS, basic and diluted | $0.02 | ($0.07) | ($0.02) | ($0.22) |
- Q2 revenue rose 55% year over year; first-half revenue rose 52%, with growth across messaging products. Life sciences companies generated $24.26 million of first-half revenue.
- Q2 gross margin edged up, while first-half margin declined, reflecting solution and delivery-channel mix. Management attributed the Q2 improvement partly to the higher-margin program-design component of its newly launched Real World Evidence solution.
- Operating expenses increased 24% in Q2 and 13% in the first half, principally from staffing and business-growth investments. Revenue grew faster than expenses.
- Operating cash flow was positive $1.86 million for the first half, versus cash used of $3.61 million in the prior-year period. Investing activities used $220,476.
- Cash and cash equivalents were $83.92 million at June 30, versus $10.52 million at year-end 2020. Current assets were $104.98 million and current liabilities $6.67 million, producing working capital of about $98.32 million and a 15.7 current ratio.
- Financing provided $71.77 million, including $70.67 million net proceeds from a public stock offering and $2.71 million from option exercises, partly offset by a $1.61 million acquisition earnout payment. The company reported no remaining earnout payments.
- Total liabilities were $6.95 million, including $393,205 of lease liabilities; the filing reports no off-balance-sheet arrangements. No conventional borrowing debt is identified in the presented statements.
Changes, outlook, and risks
- Compared with Q2 2020, the company moved from a $1.08 million net loss to $352,100 net income; first-half net loss narrowed substantially from $3.28 million to $285,277.
- The Q1 2021 public offering materially strengthened liquidity and increased shares outstanding. Common shares outstanding rose from 15.22 million at December 31, 2020 to 17.50 million at June 30, 2021; 17.62 million were outstanding July 30.
- Management expects gross margin to improve quarter over quarter for the rest of 2021 as the RWE solution expands and new, higher-margin solutions launch. No numerical revenue or earnings guidance is provided.
- Management expects operating expenses to rise quarterly for the balance of the year, including continued hiring and higher travel costs as restrictions ease; it expects professional fees to fall from Q2 levels. It does not anticipate needing additional capital for operating or planned growth needs, though acquisitions or strategic opportunities could require capital.
- COVID-19 had not caused a noticeable revenue impact through the filing date, but management cautioned that a prolonged downturn could reduce customers’ advertising and marketing budgets. Other stated uncertainties include economic conditions, regulation, capital availability, competition, and accounting changes.
- Unusual Q2 expense included approximately $300,000 of professional fees for a governance review. The company launched its RWE messaging solution and generated Q2 revenue from two brands. It reported no material pending litigation; disclosure controls were deemed effective.
Important facts for investors to verify
- Whether RWE and other new solutions sustain the expected sequential gross-margin improvement, given the first-half margin decline and channel-mix effects.
- Whether revenue growth converts into sustained operating profitability and cash generation as hiring, travel, data, and other growth costs increase.
- The effects of the public offering, option exercises, and ongoing equity compensation on dilution; Q2 diluted EPS included 757,711 incremental shares, while potentially dilutive securities were excluded in loss periods as antidilutive.
- Customer and revenue concentration in life sciences, and potential sensitivity to customers’ marketing budgets and broader economic conditions.
- The filing reports Q2 net income of $352,100 and first-half net loss of $285,277; investors should distinguish the profitable quarter from the still-loss-making year-to-date period.